drugset / Trial / NCT05031806
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT-1 PEPTIDE | Peptide | 0.08 % | Other |
| Subject | ACT-1 PEPTIDE | Peptide | 0.4 % | Other |
| Subject | ACT-1 PEPTIDE | Peptide | 2 % | Other |